Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Figitumumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Figitumumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Figitumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Figitumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Figitumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Figitumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Figitumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Figitumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Figitumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Figitumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Figitumumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Figitumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Figitumumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Figitumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Figitumumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Figitumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Figitumumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Figitumumab. |
| Equol | Equol may increase the thrombogenic activities of Figitumumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Figitumumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Figitumumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Figitumumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Figitumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Figitumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Figitumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Figitumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Figitumumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Figitumumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Figitumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Figitumumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Figitumumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Figitumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Figitumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Figitumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Figitumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Figitumumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Figitumumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Figitumumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Figitumumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Figitumumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Figitumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Figitumumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Figitumumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Figitumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Figitumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Figitumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Figitumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Figitumumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Figitumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Figitumumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Figitumumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Figitumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Figitumumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Figitumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Figitumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Figitumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Figitumumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Figitumumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Figitumumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Figitumumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Figitumumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Figitumumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Figitumumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Figitumumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Figitumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Figitumumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Figitumumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Figitumumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Figitumumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Figitumumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Figitumumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Figitumumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Figitumumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Figitumumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Figitumumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Figitumumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Figitumumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Figitumumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Figitumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Figitumumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Figitumumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Figitumumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Figitumumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Figitumumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Figitumumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Figitumumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Figitumumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Figitumumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Figitumumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Figitumumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Figitumumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Figitumumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Figitumumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Figitumumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Figitumumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Figitumumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Figitumumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Figitumumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Figitumumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Figitumumab. |